emerging biotech companies with products in phase 2 or phase 3

primary.main

1,200

newThemeBody11

molecules approved by FDA in next 5 years to come from emerging biotechs

of recent product launches underperformed sales forecasts

indegeneWhite.main

Let’s partner for #FutureReadyHealthcare

newThemeh2

Develop and commercialize your product with an experienced partner

Emerging Biotech

newThemeh1

Innovate at the commercial end of the value chain

newThemeBody5

Digital transformation of clinical trials

Enhancing brand launch with patient insights and RWD

Harnessing the power of data analytics

Regulatory Intelligence - Key to successful submissions

The metaverse now: Top 3 immediate use cases

indegeneBlack.main

Insights to build #FutureReadyHealthcare

as commercialization costs typically require $50-100 million every year

Capital

newThemeh3

as large company partnerships often yield strategic brand control

Autonomy

with pharma companies result in forfeiture of majority revenue stream

Deal structures

Emerging biotech innovators are constrained by

Focus on building revenue and growing your brand with a custom-tailored, integrated solution across the product lifecycle

Prioritize development

newThemeh4

Retain control over your IP and revenue with a trusted partner to take your product to market successfully that scales as you grow

Retain ownership of your innovation

Optimize your business with ready access to a pool of industry and medical experts with institutional knowledge in your therapeutic area

Access specialists on-demand

Maximize your revenue potential with a growth-oriented partner


                    <p>
                    From clinical development through launch to LOE (Loss of Exclusivity), our medical and commercial experts bring institutional knowledge of therapeutic areas and leverage technology to deliver meaningful outcomes at each step of the development to commercialization value chain. Our technology-led Centers of Excellence (COEs) are flexible to scale up or down quickly to align with your pace of growth.</p>

Scalable Operations

<p>Having developed capabilities organically over the last 20+ years and integrated new partners thoughtfully, we provide a cohesive experience across the product lifecycle. We seamlessly manage the complex and interdependent pharma model, from clinical, medical and commercial operations with a purpose-built model that is unified at its core. That’s why we built capabilities across the development to commercialization value chain.</p>

#FutureReadyHealthcare

Who We Are

Investor Relations

News

Careers